Literature DB >> 26787734

CD8+ T cells mediate antibody-independent platelet clearance in mice.

Connie M Arthur1, Seema R Patel1, H Cliff Sullivan1, Annie M Winkler1, Chris A Tormey2, Jeanne E Hendrickson2, Sean R Stowell1.   

Abstract

Platelet transfusion provides an important therapeutic intervention in the treatment and prevention of bleeding. However, some patients rapidly clear transfused platelets, preventing the desired therapeutic outcome. Although platelet clearance can occur through a variety of mechanisms, immune-mediated platelet removal often plays a significant role. Numerous studies demonstrate that anti-platelet alloantibodies can induce significant platelet clearance following transfusion. In fact, for nearly 50 years, anti-platelet alloantibodies were considered to be the sole mediator of immune-mediated platelet clearance in platelet-refractory individuals. Although nonimmune mechanisms of platelet clearance can often explain platelet removal in the absence of anti-platelet alloantibodies, many patients experience platelet clearance following transfusion in the absence of a clear mechanism. These results suggest that other processes of antibody-independent platelet clearance may occur. Our studies demonstrate that CD8(+)T cells possess the unique ability to induce platelet clearance in the complete absence of anti-platelet alloantibodies. These results suggest a previously unrecognized form of immune-mediated platelet clearance with significant implications in the appropriate management of platelet-refractory individuals.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26787734      PMCID: PMC4825415          DOI: 10.1182/blood-2015-10-673426

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  Platelet transfusions.

Authors:  David F Stroncek; Paolo Rebulla
Journal:  Lancet       Date:  2007-08-04       Impact factor: 79.321

2.  Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens.

Authors:  K W Bang; E R Speck; V S Blanchette; J Freedman; J W Semple
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

3.  Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia.

Authors:  Daniel W Bougie; Dhirendra Nayak; Brian Boylan; Peter J Newman; Richard H Aster
Journal:  Blood       Date:  2010-06-29       Impact factor: 22.113

4.  Transgenic mice with pancellular enhanced green fluorescent protein expression in primitive hematopoietic cells and all blood cell progeny.

Authors:  Massimo Dominici; Merhdad Tadjali; Steven Kepes; Esther R Allay; Kelli Boyd; Paul A Ney; Edwin Horwitz; Derek A Persons
Journal:  Genesis       Date:  2005-05       Impact factor: 2.487

5.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Authors:  Sherrill J Slichter; Kathryn Davis; Helen Enright; Hayden Braine; Terry Gernsheimer; Kuo-Jang Kao; Thomas Kickler; Edward Lee; Janice McFarland; Jeffrey McCullough; Glenn Rodey; Charles A Schiffer; Robert Woodson
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

Review 6.  The pathogenesis of chronic immune thrombocytopenic purpura.

Authors:  Robert McMillan
Journal:  Semin Hematol       Date:  2007-10       Impact factor: 3.851

7.  Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and {beta}2 integrin-dependent cell clearance program.

Authors:  Norma Maugeri; Patrizia Rovere-Querini; Virgilio Evangelista; Cesare Covino; Annalisa Capobianco; Maria T S Bertilaccio; Antonio Piccoli; Licia Totani; Domenico Cianflone; Attilio Maseri; Angelo A Manfredi
Journal:  Blood       Date:  2009-03-04       Impact factor: 22.113

8.  Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.

Authors:  Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Mila Lebedeva; John W Heitman; Michael P Busch; Sherrill J Slichter; Philip J Norris
Journal:  Blood       Date:  2013-02-07       Impact factor: 22.113

9.  Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice.

Authors:  Seema R Patel; Chantel M Cadwell; Arielle Medford; James C Zimring
Journal:  J Clin Invest       Date:  2009-08-10       Impact factor: 14.808

10.  Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia.

Authors:  Tamam Bakchoul; Brian Boylan; Ulrich J H Sachs; Gregor Bein; Changgeng Ruan; Sentot Santoso; Peter J Newman
Journal:  Transfusion       Date:  2008-11-04       Impact factor: 3.157

View more
  16 in total

1.  Antibody-mediated immune suppression by antigen modulation is antigen-specific.

Authors:  Cheryl L Maier; Amanda Mener; Seema R Patel; Ryan P Jajosky; Ashley L Bennett; Connie M Arthur; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood Adv       Date:  2018-11-13

2.  Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

Authors:  Johnson Q Tran; Marcus O Muench; Rachael P Jackman
Journal:  Blood Adv       Date:  2020-11-10

Review 3.  Key regulators of galectin-glycan interactions.

Authors:  Nourine A Kamili; Connie M Arthur; Christian Gerner-Smidt; Eden Tafesse; Anna Blenda; Marcelo Dias-Baruffi; Sean R Stowell
Journal:  Proteomics       Date:  2016-12       Impact factor: 3.984

4.  Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice.

Authors:  Seema R Patel; Ashley Bennett; Kathryn Girard-Pierce; Cheryl L Maier; Satheesh Chonat; Connie M Arthur; Patricia E Zerra; Amanda Mener; Sean R Stowell
Journal:  Blood Adv       Date:  2018-01-23

5.  Molecular immunohaematology round table discussions at the AABB Annual Meeting, Orlando 2016.

Authors:  Willy A Flegel; Qing Chen; Lilian Castilho; Margaret A Keller; Ellen B Klapper; William J Lane; France Pirenne; Gary Stack; Maryse St-Louis; Christopher A Tormey; Dan A Waxman; Christof Weinstock; Silvano Wendel; Gregory A Denomme
Journal:  Blood Transfus       Date:  2018-02-14       Impact factor: 3.443

6.  Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Satheesh Chonat; Andreas Wieland; Manjula Santhanakrishnan; Jingchun Liu; Cheryl L Maier; Ryan P Jajosky; Kathryn Girard-Pierce; Ashley Bennett; Patricia E Zerra; Nicole H Smith; Jeanne E Hendrickson; Sean R Stowell
Journal:  JCI Insight       Date:  2018-11-15

7.  Antibody-mediated immunosuppression can result from RBC antigen loss independent of Fcγ receptors in mice.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Sean R Stowell
Journal:  Transfusion       Date:  2018-11-26       Impact factor: 3.157

8.  Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

Authors:  Patricia E Zerra; Courtney Cox; W Hunter Baldwin; Seema R Patel; Connie M Arthur; Pete Lollar; Shannon L Meeks; Sean R Stowell
Journal:  Blood       Date:  2017-10-04       Impact factor: 22.113

9.  Antigen Density Dictates Immune Responsiveness following Red Blood Cell Transfusion.

Authors:  Connie M Arthur; Seema R Patel; Nicole H Smith; Ashley Bennett; Nourine A Kamili; Amanda Mener; Christian Gerner-Smidt; Harold C Sullivan; J Scott Hale; Andreas Wieland; Benjamin Youngblood; James C Zimring; Jeanne E Hendrickson; Sean R Stowell
Journal:  J Immunol       Date:  2017-03-01       Impact factor: 5.426

10.  Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.

Authors:  Harold C Sullivan; Christian Gerner-Smidt; Ajay K Nooka; Connie M Arthur; Louisa Thompson; Amanda Mener; Seema R Patel; Marianne Yee; Ross M Fasano; Cassandra D Josephson; Richard M Kaufman; John D Roback; Sagar Lonial; Sean R Stowell
Journal:  Blood       Date:  2017-04-03       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.